Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Mivelsiran sodium by Alnylam Pharmaceuticals for Unspecified Central Nervous System Disorders: Likelihood of Approval
Mivelsiran sodium is under clinical development by Alnylam Pharmaceuticals and currently in Phase II for Unspecified Central Nervous System Disorders....